Filing Flows › Industrials › OptimizeRx (OPRX)
OptimizeRx (OPRX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · OptimizeRx (OPRX) Q2 2026 earnings results →
Q2 2026 Revenue down 30% year over year to $20.5M · 3¢ of every $1 of revenue lost · operating margin -0.4%
OptimizeRx made $20.5M in Q2 2026 (-30% Y/Y). Operating margin -0.4%, net loss $703K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $20.5M in Q2 2026, down 30% year over year and up 3% from the previous quarter.
Operating costs exceeded revenue by $88K, an operating margin of -0.4%. The fastest-growing cost line was Other operating costs (+28%). The quarter ended with a net loss of $703K, wider than the previous quarter's $495K loss. Net interest and other expense of $1.0M was the main reason.
Operating cash flow was $8.6M (up 89% year over year). Non-cash charges added back $1.1M of depreciation and amortization and $2.2M of share-based compensation. Working capital and other items added $6.0M. Capital expenditures of $35K left free cash flow of $8.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $20.5M | -30% | -0.4% | −$703K | $8.6M |
| Q1 2026 | 10-Q | May 13, 2026 | $19.8M | -10% | 2.0% | −$495K | −$467K |
| Q4 2025 | 10-K | Mar 12, 2026 | $32.2M | -0.2% | 26.6% | $5.0M | $7.1M |
| Q3 2025 | 10-Q | Nov 7, 2025 | $26.1M | +22% | 7.9% | $779K | $3.2M |
| Q2 2025 | 10-Q | Aug 8, 2025 | $29.2M | +55% | 11.0% | $1.5M | $4.6M |
| Q1 2025 | 10-Q | May 13, 2025 | $21.9M | +11% | -9.6% | −$2.2M | $3.9M |
| Q4 2024 | 10-K | Mar 20, 2025 | $32.3M | +14% | 11.2% | −$78K | $198K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About OptimizeRx
OptimizeRx is a leading digital healthcare technology company that is redefining how life sciences brands engage with, market their services and products to, and support patients and healthcare providers. We leverage our proprietary technology solutions and partnerships to help our clients develop and execute highly individualized and targeted marketing campaigns to drive physician and patient engagement and to enhance patient care. OptimizeRx is a Nevada corporation and was founded in 2006 in Rochester, Michigan, as a healthcare technology company delivering various types of messages to target audiences, including coupons and co-pays directly to physicians and pharmacists through electronic health record (“EHR”) systems and ePrescribing (“eRx”) platforms.
In its own words, from its 10-K, filed Mar 12, 2026.
OptimizeRx against its Services-Business Services, NEC peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -30% against the peers' median +10%. Operating margin: -0.4% against the peers' median 9.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| OPRX OptimizeRx | Q2 2026 | $20.5M | -30% | -0.4% |
| ACN Accenture | Q4 FY26 | $18.7B | +6% | 15.3% |
| UBER Uber Technologies | Q3 2026 | $14.8B | +10% | 9.8% |
| V Visa | Q4 FY26 | $12.1B | +13% | 59.8% |
| MELI MercadoLibre | Q3 2026 | $10.8B | +45% | 6.3% |
| MA Mastercard | Q3 2026 | $9.8B | +14% | 59.8% |
| PYPL PayPal Holdings | Q3 2026 | $8.6B | +2% | 16.3% |
| FISV Fiserv | Q3 2026 | $5.2B | -1% | -105.7% |
| DASH DoorDash | Q3 2026 | $4.6B | +34% | 9.6% |
Source: OptimizeRx 10-Q on SEC EDGAR · CIK 1448431 · Services-Business Services, NEC
13F: who owns OPRX and who is buying
More on OPRX
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results